Advertisement

Topics

Allogene started our with 17 off-the-shelf CAR-T assets licensed from Cellectis by way of Pfizer. All but one had not yet been tested in humans. https://www.fiercebiotech.com/biotech/5-months-after-launch-allogene-guns-for-100m-ipo …

13:20 EDT 14 Sep 2018 | Odi Bruckman

Allogene started our with 17 off-the-shelf CAR-T assets licensed from Cellectis by way of Pfizer. All but one had not yet been tested in humans. https://www.fiercebiotech.com/biotech/5-months-after-launch-allogene-guns-for-100m-ipo …

Original Article: Allogene started our with 17 off-the-shelf CAR-T assets licensed from Cellectis by way of Pfizer. All but one had not yet been tested in humans. https://www.fiercebiotech.com/biotech/5-months-after-launch-allogene-guns-for-100m-ipo …

NEXT ARTICLE

More From BioPortfolio on "Allogene started our with 17 off-the-shelf CAR-T assets licensed from Cellectis by way of Pfizer. All but one had not yet been tested in humans. https://www.fiercebiotech.com/biotech/5-months-after-launch-allogene-guns-for-100m-ipo …"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...